---
schema_version: "secwatch.filing_event.v1"
accession: "0001447028-24-000084"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T15:19:36.791479+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CSO Michael J. Sofia to retire Dec 31, 2024; amendment clarifies severance and non-compete

## Summary
- CSO Michael J. Sofia will retire effective December 31, 2024; amendment to employment agreement dated Oct 11, 2024.
- Sofia eligible for 2024 annual target cash bonus ($204,800) prorated by corporate score, payable ~Feb 15, 2025.
- Amendment carves out coronavirus and HDV-only treatments from non-compete; also allows academic teaching/research.
- Sofia must sign release to receive benefits; 21-day consideration period and 7-day revocation.
- No named replacement; retirement is planned, not abrupt.

## SEC filing metadata
- accession: 0001447028-24-000084
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000144702824000084/0001447028-24-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000144702824000084/abus-20241011.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447028-24-000084
- JSON: https://secwatch.observer/filing/0001447028-24-000084.json
- Plain text: https://secwatch.observer/filing/0001447028-24-000084.txt

## Key facts
- Executive change
  Michael J. Sofia retired as Chief Scientific Officer at Arbutus Biopharma Corp.
  - Action: retired
  - Role: Chief Scientific Officer
  source text: As previously disclosed, Michael J. Sofia announced his retirement as Chief Scientific Officer of Arbutus Biopharma, Inc. (the “Company”), a subsidiary of Arbutus Biopharma Corporation, effective December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000144702824000084/0001447028-24-000084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.